Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00477529 | ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer | PHASE1 | COMPLETED | 102 | — | — | Apr 1, 2007 | Jun 2, 2011 | Nov 22, 2019 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| ABI-008 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABI-008 | DRUG | nab-docetaxel |
Inclusion Criteria: Each subject must meet the following criteria to be enrolled in this study. 1. Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate that is clinically refractory to hormone therapy. 2. Zubrod Performance Status 0-1. 3. At the time of enrol...